cholecalciferol and Nervous-System-Diseases

cholecalciferol has been researched along with Nervous-System-Diseases* in 4 studies

Reviews

1 review(s) available for cholecalciferol and Nervous-System-Diseases

ArticleYear
[Skeletal and extra-skeletal consequences of vitamin D deficiency].
    Orvosi hetilap, 2011, Aug-14, Volume: 152, Issue:33

    Vitamin D is obtained from cutaneous production when 7-dehydrocholesterol is converted to vitamin D(3) (cholecalciferol) by ultraviolet B radiation or by oral intake of vitamin D. Rickets appeared to have been conquered with vitamin D intake, and many health care professionals thought the major health problems resulting from vitamin D deficiency had been resolved. However, rickets can be considered the tip of the vitamin D deficiency iceberg. In fact, vitamin D deficiency remains common in children and adults. An individual's vitamin D status is best evaluated by measuring the circulating 25-hydroxyvitamin D (25(OH)D3) concentration. There is increasing agreement that the optimal circulating 25(OH)D3 level should be approximately 30 ng/mL or above. Using this definition, it has been estimated that approximately three-quarters of all adults have low levels. In utero and during childhood, vitamin D deficiency can cause growth retardation and skeletal deformities and may increase the risk of hip fracture later in life. Vitamin D deficiency in adults can exacerbate osteopenia and osteoporosis, cause osteomalacia and muscle weakness, and increase the risk of fracture. More recently, associations between low vitamin D status and increased risk for various non-skeletal morbidities have been recognized; whether all of these associations are causally related to low vitamin D status remains to be determined. The discovery that most tissues and cells in the body have vitamin D receptors and that several possess the enzymatic machinery to convert the 25-hydroxyvitamin D3, to the active form, 1,25-dihydroxyvitamin D3, has provided new insights into the function of this vitamin. Of great interest is its role in decreasing the risk of many chronic illnesses, including common cancers, autoimmune diseases, infectious diseases, and cardiovascular disease. In this review I consider the nature of vitamin D deficiency, discuss its role in skeletal and non-skeletal health, and suggest strategies for prevention and treatment.

    Topics: Asthma; Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cholecalciferol; Dietary Supplements; Ergocalciferols; Humans; Metabolic Syndrome; Nervous System Diseases; Parathyroid Hormone; Rickets; Risk Factors; Sunlight; Vitamin D; Vitamin D Deficiency

2011

Other Studies

3 other study(ies) available for cholecalciferol and Nervous-System-Diseases

ArticleYear
Vitamin D deficiency induces the excitation/inhibition brain imbalance and the proinflammatory shift.
    The international journal of biochemistry & cell biology, 2020, Volume: 119

    Vitamin D

    Topics: Animals; Brain; Cholecalciferol; Cholesterol; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamic Acid; Inflammation; Male; Membrane Fusion; Mice, Inbred C57BL; Nervous System Diseases; Neural Pathways; Phospholipids; Rats; Rats, Wistar; Reactive Oxygen Species; Receptors, Metabotropic Glutamate; Synapses; Vitamin D Deficiency; Vitamins

2020
Dietary supplementation exerts neuroprotective effects in ischemic stroke model.
    Rejuvenation research, 2008, Volume: 11, Issue:1

    This study examined whether dietary supplementation can be used to protect against ischemic stroke. Two groups of adult male Sprague-Dawley rats initially received NT-020, a proprietary formulation of blueberry, green tea, Vitamin D3, and carnosine (n = 8), or vehicle (n = 7). Dosing for NT-020 and vehicle consisted of daily oral administration (using a gavage) over a 2-week period. On day 14 following the last drug treatment, all animals underwent the stroke surgery using the transient 1-hour suture occlusion of middle cerebral artery (MCAo). To reveal the functional effects of NT-020, animals were subjected to established behavioral tests just prior to stroke surgery and again on day 14 post-stroke. ANOVA revealed significant treatment effects (p < 0.05), characterized by reductions of 11.8% and 24.4% in motor asymmetry and neurologic dysfunction, respectively, in NT-020-treated stroke animals compared to vehicle-treated stroke animals. Evaluation of cerebral infarction revealed a significant 75% decrement in mean glial scar area in the ischemic striatum of NT-020-treated stroke animals compared to that of vehicle-treated stroke animals (p < 0.0005). Quantitative analysis of subventricular zone's cell proliferative activity revealed at least a one-fold increment in the number of BrdU-positive cells in the NT-020-treated stroke brains compared to vehicle-treated stroke brains (p < 0.0005). Similarly, quantitative analysis of BrdU labeling in the ischemic striatal penumbra revealed at least a three-fold increase in the number of BrdU-positive cells in the NT-020-treated stroke brains compared to vehicle-treated stroke brains (p < 0.0001). In addition, widespread double labeling of cells with BrdU and doublecortin was detected in NT-020-treated stroke brains (intact side 17% and ischemic side 75%), which was significantly higher than those seen in vehicle-treated stroke brains (intact side 5% and ischemic side 13%) (p < 0.05). In contrast, only a small number of cells in NT-020-treated stroke brains double labeled with BrdU and GFAP (intact side 1% and ischemic side 2%), which was significantly lower than those vehicle-treated stroke brains (intact side 18% and ischemic side 35%) (p < 0.0001). Endogenous neurogenic factors were also significantly upregulated in the ischemic brains of NT-020-treated stroke animals. These data demonstrate the remarkable neuroprotective effects of NT-020 when given prior to stroke, possibly acting via its neurogenic potential

    Topics: Animals; Blueberry Plants; Brain Ischemia; Carnosine; Cell Differentiation; Cholecalciferol; Dietary Supplements; Disease Models, Animal; Doublecortin Protein; Drugs, Chinese Herbal; Male; Nervous System Diseases; Neurons; Neuroprotective Agents; Plant Extracts; Rats; Rats, Sprague-Dawley; Stroke; Tea

2008
[Idiopathic hypoparathyroidism with neurological manifestations: successful treatment with vitamin D3].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2001, Feb-10, Volume: 90, Issue:2

    Topics: Cholecalciferol; Humans; Hypoparathyroidism; Male; Middle Aged; Nervous System Diseases

2001